Skip to main content
SpringerLink
Log in

Significance of an abnormal response during pituitary desensitization in an in vitro fertilization and embryo transfer program

  • Clinical Assisted Reproduction
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose: Our purpose was to evaluate the IVF-ET outcome in patients who did not achieve timely pituitary-ovarian suppression following “long”-protocol GnRH agonist (GnRH-a) administration.

Methods: A retrospective analysis was done on 96 IVF treatment cycles characterized by a delayed response (DR) to long-protocol GnRH-a treatment. The study included those patients who either achieved ovarian suppression (E2 ≤ 110 pM) despite an elevated LH level (group DR-A) or had pituitary desensitization (LH ≤ 1.5 IU/L) without ovarian suppression (group DR-B) on day 12 of GnRH-a treatment but needed an extended course of GnRH-a treatment to achieve complete suppression. These patients had gonadotropin stimulation either from day 12, despite an elevated level of LH (subgroup DR-A1; n=13) or elevated E2 levels (subgroup DR-B1; n=9), or after achieving a complete hypogonadotropic-hypopgonadal state following an extended course of GnRH-a treatment [subgroups DR-A2 (n=46) and DR-B2 (n=28)]. The outcome was compared with that of 88 cycles of normal responders (group NR) who had pituitary-ovarian suppression by day 12 of GnRH-a administration.

Results: Ovarian response and pregnancy rates in subgroups DR-A1 and DR-A2 were statistically not different and comparable to those in the NR group. In subgroups DR-B1 and DR-B2, E2 response and rates of oocyte retrieval and pregnancy were significantly lower than those in the other groups, but fertilization and cleavage rates were similar. The requirement of gonadotropin for ovarian stimulation was comparatively higher in subgroup DR-A2 and both DR-B subgroups.

Conclusions: There was no treatment cancellation in group NR and both DR-A subgroups, but 22% of the cycles in DR-B1 and 14% of the cycles in DR-B2 were canceled due to poor ovarian response. It therefore appears that during long-protocol pituitary desensitization, the post-GnRH-a level of serum E2, rather than LH, better predicts IVF-ET outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Insler V, Lunenfeld B: Human gonadotropins.In Infertility: Male and Female, V Insler, B Lunenfeld (eds). New York, Churchill Livingstone, 1993, pp. 387–417

    Google Scholar 

  2. Fleming R, Coutts JRT: Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression. Fertil Steril 1986;45:226–230

    PubMed  Google Scholar 

  3. Eibschitz I, Belaisch-Allart JC, Frydman R: In vitro fertilization management and results in stimulated cycles with spontaneous luteinizing hormone discharge. Fertil Steril 1986;45:231–236

    PubMed  Google Scholar 

  4. Schmutzler RK, Reichert C, Diedrich K, Wildt I, Diedrich C, Al Hasani S,et al.: Combined GnRH-agonist/gonadotropin stimulation for in vitro fertilization. Hum Reprod 1988;3(Suppl 4):29–33

    Google Scholar 

  5. Droesch K, Muasher SH, Brzyski RG, Jones GS, Simonetti S, Liu H-C, Rosenwaks Z: Value of suppression with a gonadotropin releasing hormone agonist prior to gonadotropin stimulation for IVF. Fertil Steril 1989;51:292–297

    PubMed  Google Scholar 

  6. San Roman GA, Surrey ES, Judd H L, Kerin JF: A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin releasing hormone agonist for in vitro fertilization. Fertil Steril 1992;58:744–749

    PubMed  Google Scholar 

  7. Ron-El R, Herman A, Golan A, Soffer Y, Nachum H, Caspi E: Ultrashort gonadotropin releasing hormone agonsist (GnRH-a) protocol in comparison with the long-acting GnRH-a protocol and menotropin alone. Fertil Steril 1992;58:1164–1168

    PubMed  Google Scholar 

  8. Seifer DB, Thornton KL, DeCherney AH, Lavy G: Early pituitary desensitization and ovarian suppression with leuprolide acetate is associated with in vitro fertilization-embryo transfer success. Fertil Steril 1991;56:500–504

    PubMed  Google Scholar 

  9. Penzias AS, Lee G, Seifer DB, Shamma FN, DeCherney A H, Reindollar RH, Jones EE: Aberrant estradiol flare despite gonadotropin-releasing hormone-agonist-induced suppression is associated with impaired implantation. Fertil Steril 1994;61:558–560

    PubMed  Google Scholar 

  10. World Health Organization: WHO Laboratory Manual for the Examination of Human Semen and Semen-Cervical Mucus Interaction, 2nd ed. Cambridge, Cambridge University Press, 1987, Vol 3, p 27

    Google Scholar 

  11. Fluker MR, Monroe SE, Marshall LA, Jaffe RB: Contrasting effects of a gonadotropin-releasing hormone agonist and antagonist on the secretion of free alpha subunit. Fertil Steril 1994;61:573–575

    PubMed  Google Scholar 

  12. Meldrum DR, Tsao Z, Monroe SE, Braunstein GD, Sladek J, Lu JKH, Vale W, Rivier J, Judd HL, Chang RJ: Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women. J Clin Endocrinol Metab 1984;58:755–757

    PubMed  Google Scholar 

  13. Lincoln SR, Long CA, Whitworth NS, Sopelak VM, Cowan BD: Elevated luteinizing hormone on the day of human chorionic gonadotropin administration does not reduce cycle fecundity in a low-dose flare-up in vitro fertilization protocol. Fertil Steril 1995;63:563–565

    PubMed  Google Scholar 

  14. Ben-Rafael Z, Menashe Y, Mimon R, Lipitz S, Bider D, Zolti M,et al.: Limitations in the use of combined gonadotropin releasing hormone analog and human menopausal gonadotropin for din vitro fertilization.In Advances in Assisted Reproductive Technologies, S Mashiach, Z Ben-Rafel, N Laufaer, J Schenker (eds). New York, Plenum Press, 1990, pp 17–29

    Google Scholar 

  15. Dahl KD, Bicsak TA, Hsueh AJ: Naturally occurring antihormones: Secretion of FSH antagonists by women treated with a GnRH-analog. Science 1988;239:72–74

    PubMed  Google Scholar 

  16. Scott RT, Neal GS, Illions EH, Hayslip CA, Hofmann GE: The duration of leuprolide acetate administration piror to ovulation induction does not impact ovarian responsiveness to exogenous gonadotropins. Fertil Steril 1993;60:247–253

    PubMed  Google Scholar 

  17. Chang SY, Lee CL, Wang ML, Hu ML, Lai YM, Chang MY, Soong YK: No detrimental effects in delaying initiation of gonadotropin administration after pituitary desensitization with gonadotropin-releasing hormone agonist. Fertil Steril 1993;59:183–186

    PubMed  Google Scholar 

  18. Insler V, Lunenfeld E, Potashnik G, Levy J: Ovarian stimulation concomitant with pituitary-ovarian axis suppression by different GnRH-agonists. Int J Fertil 1991;36:121–127

    PubMed  Google Scholar 

  19. Conn PM, Crowley WF: Gonadotropin releasing hormone and its analogues. N Engl J Med 1991;324:93–103

    PubMed  Google Scholar 

  20. Balasch J, Jové IC, Moreno V, Civico S, Puerto B, Vanrell JA: The comparison of two gonadotropin-releasing hormoneagonists in an in vitro fertilization program. Fertil Steril 1992;58:991–994

    PubMed  Google Scholar 

  21. Nestor JJ, Ho TL, Tahilramani R, McRae GI, Vickery BH: Long acting LHRH agonists and antagonists.In LHRH and Its Analogues: Basic and Clinical Aspects, F Labrie, A Bélanger, A Dupont (eds). Amsterdam, Excerpta Medica, 1984, pp 24–35

    Google Scholar 

  22. Miro F, Sampaio MC, Tarin JJ, Pellicer A: Steroidogenesis in vitro of human granulosa-luteal cells pretreated in vivo with two gonadotropin releasing hormone analogs employing different protocols. Gynecol Endocrinol 1992;6:77–84

    PubMed  Google Scholar 

  23. Hull MGR, Armatage RJ, McDermott A: Use of follicle-stimulating hormone alone (urofollitropin) to stimulate the ovaries for assisted conception after pituitary desensitization. Fertil Steril 1994;62:997–1003

    PubMed  Google Scholar 

  24. Edelstein MC, Brzyski RG, Jones GS, Simonetti S, Muasher SJ: Equivalency of human menopausal gonadotropin and follicle-stimulating hormone stimulation after gonadotropin-releasing hormone-agonist suppression. Fertil Steril 1990;53:103–106

    PubMed  Google Scholar 

  25. Neveu S, Hedom B, Bringer J, Chinchole J-M, Arnal F, Humeau C,et al.: Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization. Fertil Steril 1987;47:639–664

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Assisted Reproductive Technology, Institute of Reproductive Medicine, DD 18/5/1, 700 064, Salt Lake City, Calcutta, India

    S. K. Goswami & B. N. Chakravarty

  2. Department of Reproductive Biology Research, Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Jadavpur, 700 032, Calcutta, India

    Syed N. Kabir

Authors
  1. S. K. Goswami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. N. Chakravarty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Syed N. Kabir
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goswami, S.K., Chakravarty, B.N. & Kabir, S.N. Significance of an abnormal response during pituitary desensitization in an in vitro fertilization and embryo transfer program. J Assist Reprod Genet 13, 374–380 (1996). https://doi.org/10.1007/BF02066167

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02066167

Key words

Search

Navigation